TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 阿尔茨海默病(简称AD)是一种导致思维和记忆能力日益困难的疾病。思维和记忆力的衰退被称为“痴呆症”，阿尔茨海默病是美国最常见的痴呆症原因。阿尔茨海默病的确切原因尚不清楚。有证据表明，减缓或帮助预防阿尔茨海默病的一种方法可能是降低胆固醇。这项研究项目将研究一种名为辛伐他汀的药物是否也有助于减轻AD症状。辛伐他汀是FDA批准的一种通常用于降低胆固醇的药物。预计将有大约10名参与者在该网站注册。将有400名参与者在美国约40个研究地点登记参加这项研究。要被登记，一个人必须在50岁及以上，并有阿尔茨海默病的诊断。医疗条件和身体健康必须是可接受的，由病史、医生检查和实验室测试确定。一些人可能没有资格参加，如果他们使用的药物是不允许的，或者如果医生根据一系列认知和身体测试的结果确定他们不符合资格。如果一个人怀孕或对研究药物过敏，他们一定不能参加。参与者将被随机分配接受辛伐他汀或安慰剂。随机意味着偶然，就像抛硬币一样。安慰剂指的是一种非活性物质，有时被称为“假药丸”或“糖丸”。安慰剂预计不会对AD有任何影响。参与者将服用为期18个月的学习药物，并将来诊所8次。在门诊期间，他们将进行思维和记忆力测试，并抽取血样。研究人员将测量服用辛伐他汀的人与服用安慰剂的人在思维和记忆能力方面是否存在差异。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's disease (abbreviated AD) is an illness that causes increasing difficulty in the ability to think and remember. The decline of thinking and memory is known as "dementia," and AD is the most common cause of dementia in the U.S. The exact cause of AD is not known. There is some evidence that one way to slow down or help prevent AD may be to lower cholesterol. This research project will study whether a drug called simvastatin, which is an FDA-approved drug commonly used to lower cholesterol, might also help reduce AD symptoms. Approximately 10 participants are expected to be enrolled at this site. There will be 400 participants enrolled in this research study at approximately 40 study sites in the United States. To be enrolled, a person must be 50 years old and above and have a diagnosis of Alzheimer's disease. Medical condition and physical health must be acceptable as determined by medical history, a doctor's examination and laboratory tests. Some people may not be eligible to participate if they are using medications that are not allowed, or if the doctor determines they do not qualify based on their results from a set of cognitive and physical tests. If a person is pregnant or allergic to study medication, they must not participate. People who participate will be randomly assigned to receive simvastatin or a placebo. Randomly means by chance, like flipping a coin. Placebo means an inactive substance, sometimes called a "dummy pill" or "sugar pill." A placebo is not expected to have any effect on AD. Participants will take study medication for 18 months, and will come to the clinic 8 times. During the clinic visits, they will have tests of their thinking and memory, and blood samples will be drawn. Researchers will measure whether there is any difference in thinking and memory skills between people who were on simvastatin compared to people who were on placebo.'